EUVIMEDEUVIMED entdecken
Systematische Übersicht

A systematic literature review of economic evaluations of setmelanotide

Andrej Belančić, Elvira Meni Maria Gkrinia, Eda Kübra Sel, Rossana Roncato, Slobodan Janković, Dinko Vitezić

European Journal of Clinical Pharmacology · 2026-05 · 82 (5)

DOI: 10.1007/s00228-026-04058-y ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 20.04.2026. Verfasst von Andrej Belančić und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Braće Branchetta 20, Rijeka, 51000, Croatia.…. Hauptthemen laut MEDLINE: alpha-MSH, Obesity. Die Arbeit nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This systematic literature review (SLR) aimed to assess the economic value of setmelanotide, a selective melanocortin-4 receptor agonist, in the treatment of rare genetic diseases of obesity (RGDOs), specifically Bardet-Biedl syndrome (BBS), pro-opiomelanocortin (POMC) deficiency, and leptin receptor (LEPR) deficiency. METHODS: The SLR was conducted according to PRISMA guidelines and registered on PROSPERO. Systematic searches were performed in Embase, MEDLINE/PubMed, and Global Health, supplemented by manual searches and reference screening. Inclusion criteria included full economic evaluations (cost-effectiveness and cost-utility analyses) published in English since 2019. Data extraction and quality assessment followed established checklists (BMJ, CHEERS 2022), with findings synthesised descriptively due to heterogeneity in study designs and settings. RESULTS: Four studies (one CEA, three CUAs) met inclusion criteria, all employing model-based frameworks from a healthcare payer perspective with a lifetime horizon. Incremental cost-effectiveness ratios (ICERs) varied: NICE appraisals in the UK suggested potentially favorable or even negative ICERs, while the Canadian CADTH review reported ICERs exceeding CAD $2 million/QALY, far above conventional willingness-to-pay thresholds. Key drivers included drug acquisition cost, severity of hyperphagia, and caregiver burden. All studies noted significant uncertainty due to limited long-term data and small patient populations. CONCLUSIONS: While setmelanotide demonstrates clinical benefit in RGDOs, its high cost poses substantial challenges to conventional pharmacoeconomic evaluations. Adoption may require significant price reductions or alternative value assessment frameworks, particularly for rare diseases. Further research is needed to address long-term effectiveness and ethical considerations in economic evaluations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-MSHObesityHumansCost-Benefit AnalysisCost-Effectiveness AnalysisReceptor, Melanocortin, Type 4Pro-Opiomelanocortin

Stichwörter der Autor:innen

Cost-effectiveness analysisCost-utility analysisEconomic evaluationObesitySetmelanotide

Substanzen

alpha-MSHsetmelanotideReceptor, Melanocortin, Type 4Pro-Opiomelanocortin

Autor:innen und Institutionen

  • Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Braće Branchetta 20, Rijeka, 51000, Croatia. andrej.belancic@uniri.hr.
  • , Athens, Greece. elvira.gkrinia20@alumni.imperial.ac.uk.
  • Department of Medical Pharmacology, Faculty of Medicine, Dokuz Eylul University, Izmir, Türkiye.
  • Department of Medicine, University of Udine, Udine, Italy.
  • Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
  • Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Braće Branchetta 20, Rijeka, 51000, Croatia.

Zitieren

APA

Belančić, A., Gkrinia, E. M. M., Sel, E. K., Roncato, R., Janković, S., & Vitezić, D. (2026). A systematic literature review of economic evaluations of setmelanotide. European Journal of Clinical Pharmacology, 82(5). https://doi.org/10.1007/s00228-026-04058-y

Vancouver

Belančić A, Gkrinia EMM, Sel EK, Roncato R, Janković S, Vitezić D. A systematic literature review of economic evaluations of setmelanotide. European Journal of Clinical Pharmacology. 2026;82(5). doi:10.1007/s00228-026-04058-y

BibTeX
@article{Belani2026,
  author = {Belančić, Andrej and Gkrinia, Elvira Meni Maria and Sel, Eda Kübra and Roncato, Rossana and Janković, Slobodan and Vitezić, Dinko},
  title = {A systematic literature review of economic evaluations of setmelanotide},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  volume = {82},
  number = {5},
  doi = {10.1007/s00228-026-04058-y}
}
Kostenlos starten →